Partnership discussions for IDIX’s IDX899 HIV drug are in progress and the program will be partnered in late 2008 following the completion of a six-week study of IDX899+Truvada vs Sustiva+Truvada, according to JP Sommadossi. The intent to partner this program is old news but the guidance for an announced deal in 2008 is new.
Source: Today’s Susquehanna webcast
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”